• Search History (Register)
  • MeSH Browser

Welcome to the international HTA database


Showing [21597 Records] Selected Records [0 Hits] [Clear]
Year Source Title
2023     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Maralixibat (cholestatic pruritis) - Assessment according to §35a (para. 1, sentence 11) Social Code Book V]
2023     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Valoctocogen roxaparvovec (haemophilia) - Assessment according to §35a (para. 1, sentence 11) Social Code Book V]
2023     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Cold plasma in wound therapy (2nd addendum to Commission E21-03)]
2023     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Cold plasma in wound therapy]
2023     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Daridorexant (insomnia) - Addendum to Commission A22-123]
2023     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Dolutegravir/abacavir/lamivudine (HIV infection in children) - Benefit assessment according to §35a Social Code Book V]
2023     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Voclosporin (lupus nephritis) - Benefit assessment according to §35a Social Code Book V]
2023     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Finerenone (CKD stage 2 and 3) - Benefit assessment according to §35a Social Code Book V]
2023     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Finerenone (CKD stage 1 and 2) - Benefit assessment according to §35a Social Code Book V]
2023     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Relugolix (prostate cancer) - Addendum to Commission A22-108]
2023     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Vutrisiran (hereditary transthyretin amyloidosis with polyneuropathy) - Addendum to Commission A22-114]
2023     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Dapagliflozin (heart failure with preserved ejection fraction) - Benefit assessment according to §35a Social Code Book V]
2023     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Emicizumab (haemophilia A) - Benefit assessment according to §35a Social Code Book V]
2023     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Trastuzumab deruxtecan (gastric cancer) - Benefit assessment according to §35a Social Code Book V]
2023     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Trastuzumab deruxtecan (breast cancer) - Benefit assessment according to §35a Social Code Book V]
2023     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Sotorasib (NSCLC) - Benefit assessment according to §35a Social Code Book V]
2023     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Spesolimab (generalized pustular psoriasis) - Benefit assessment according to §35a Social Code Book V]
2023     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Ibrutinib (chronic lymphocytic leukaemia, first line) - Benefit assessment according to §35a Social Code Book V]
2023     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Olaparib (prostate cancer) - Benefit assessment according to § 35a SGB V]
2023     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Lutetium vipivotide tetraxetan (prostate cancer) - Benefit assessment according to §35a Social Code Book V]
2023     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Review of the study protocol and statistical analysis plan on routine practice data collection for brexucabtagene autoleucel acc. to the Law for More Safety in the Supply of Medicines (GSAV) - Addendum to commission A21-130]
2023     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Tezepelumab (severe asthma) - Benefit assessment according to § 35a SGB V]
2023     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Concept for routine practice data collection for etranacogene dezaparvovec acc. to the Law for More Safety in the Supply of Medicines (GSAV)]
2023     Health Information and Quality Authority (HIQA) Health technology assessment of domiciliary invasive ventilation for adults with spinal cord injuries
2023     Health Information and Quality Authority (HIQA) International review of the epidemiology of long COVID
2023     Penn Medicine Center for Evidence-based Practice (CEP) Urine pregnancy screening for patients with and without the capacity for pregnancy
2023     Austrian Institute for Health Technology Assessment (AIHTA) [Sponsoring of patient initiatives in Austria. 5th update of the systematic analyses 2014 to 2019]
2023     Institut national d'excellence en sante et en services sociaux (INESSS) [State of knowledge: principles and criteria for gene selection for the molecular diagnosis of constitutional genetic diseases by next-generation sequencing - Report in support of the deployment of the sequencing service]
2023     Austrian Institute for Health Technology Assessment (AIHTA) [Update PET/PET-CT evidence for need based planning in the area of oncology]
2023     Austrian Institute for Health Technology Assessment (AIHTA) Perinatal and infant mental health care in Austria. A mapping of existing prevention, screening and care structures, with a specific focus on Tyrol
2023     Penn Medicine Center for Evidence-based Practice (CEP) Guidelines and clinical pathways for management of acute lower GI bleeding
2023     Scientific Advice Unit, avalia-t; The Galician Health Knowledge Agency (ACIS) [Stereotactic virtual navigation systems for percutaneous tumour ablation]
2023     NIHR Health Technology Assessment programme Clinical and cost effectiveness of endoscopic bipolar radiofrequency ablation for the treatment of malignant biliary obstruction: a systematic review
2023     Finnish Coordinating Center for Health Technology Assessment (FinCCHTA) Thermidas thermal imaging system
2023     Institut national d'excellence en sante et en services sociaux (INESSS) [Report: relevance of adding the HbS/E, HbE/E and HbE/β-thal variants to the primary targets of the neonatal screening test for hemoglobinopathies]
2023     NIHR Health Technology Assessment programme Mortality impact, risks, and benefits of general population screening for ovarian cancer: the UKCTOCS randomised controlled trial
2023     Australian Safety and Efficacy Register of New Interventional Procedures -Surgical (ASERNIP-S) Trends in utilisation of ultrasound by older Australians (2010-2019)
2023     Australian Safety and Efficacy Register of New Interventional Procedures -Surgical (ASERNIP-S) The clinical effectiveness of denosumab (Prolia) in patients with hormone-sensitive cancer receiving endocrine therapy, compared to bisphosphonates, selective estrogen receptor modulators (SERM), and placebo: a systematic review and network meta-analysis
2023     NIHR Health and Social Care Delivery Program Mental health crisis care for children and young people aged 5 to 25 years: the CAMH-Crisis evidence synthesis
2023     Austrian Institute for Health Technology Assessment (AIHTA) Oral and parenteral preexposure prophylaxis (PrEP) to prevent HIV in people at risk: a systematic review of clinical effectiveness and safety with assessment of organisational, economic, patient/social, ethical and legal elements
2023     Institut national d'excellence en sante et en services sociaux (INESSS) [Report: perineal and pelvic rehabilitation for the prevention and treatment of pelvic floor dysfunctions - Part 2: Anorectal dysfunction, pelvic organ prolapse and perineal pain in women]
2023     Austrian Institute for Health Technology Assessment (AIHTA) [Extracorporeal shock wave therapy for orthopaedic indications]
2023     Austrian Institute for Health Technology Assessment (AIHTA) [IV immunoglobulins (IgVena) in recurrent in vitro fertilisation implantation failure and/or recurrent pregnancy loss]
2023     Institut national d'excellence en sante et en services sociaux (INESSS) [State of knowledge: osseointegration of bone-anchored prostheses in individuals living with lower limb amputation(s)]
2023     Institut national d'excellence en sante et en services sociaux (INESSS) [Report: NGAL assay for the detection of acute kidney injury]
2023     Institut national d'excellence en sante et en services sociaux (INESSS) [Report: NK cell degranulation (natural killer)]
2023     Institut national d'excellence en sante et en services sociaux (INESSS) [State of knowledge: impact of physical activity on the adverse effects of cancer and cancer treatments in adults]
2023     Institut national d'excellence en sante et en services sociaux (INESSS) [State of knowledge: analysis of personal and clinical characteristics associated with a favourable response to psychosocial interventions aimed at preventing and treating common mental disorders and symptoms]
2023     Swedish Agency for Health Technology Assessment and Assessment of Social Services (SBU) Interventions to prevent and reduce gang-related crime among children and young adults
2023     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Extent of hysterectomy for endometriosis and / or adenomyosis of the uterus - Evidence report for the S3 guideline on diagnosis and treatment of benign diseases of the uterus]
2023     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [UAE and MRgFUS versus myoma enucleation - Evidence report for the S3 guideline on diagnosis and treatment of benign diseases of the uterus]
2023     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Myomectomy versus no treatment - Evidence report for the S3 guideline on diagnosis and treatment of benign diseases of the uterus]
2023     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Access routes of hysterectomy - Evidence report for the S3 guideline on diagnosis and treatment of benign diseases of the uterus]
2023     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [In-toto thrombectomy using a retriever/aspiration system for acute pulmonary artery embolism - Addendum to commission H22-04]
2023     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Sutimlimab (haemolytic anaemia in adult patients with cold agglutinin disease) - Assessment according to §35a (para. 1, sentence 11) Social Code Book V]
2023     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Abemaciclib (breast cancer; combination with an aromatase inhibitor) - Benefit assessment according to §35a Social Code Book V]
2023     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Bictegravir/ emtricitabine/ tenofovir alafenamide (HIV infections in children and adolescents) - Benefit assessment according to § 35a SGB V]
2023     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Risankizumab (Crohn’s disease) - Benefit assessment according to § 35a SGB V]
2023     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Selinexor (multiple myeloma, = 1 prior therapy) - Addendum to Commission A22-100]
2023     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Zanubrutinib (chronic lymphocytic leukaemia, relapsed/refractory) - Benefit assessment according to §35a Social Code Book V]
2023     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Zanubrutinib (marginal zone lymphoma) - Benefit assessment according to §35a Social Code Book V]
2023     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Zanubrutinib (chronic lymphocytic leukaemia, first line) - Benefit assessment according to §35a Social Code Book V]
2023     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Latanoprost/netarsudil (glaucoma) - Benefit assessment according to §35a Social Code Book V]
2023     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Systemic therapy for children and adolescents as a psychotherapy method]
2023     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Maribavir (cytomegalovirus infection (treatment-refractory)) - Assessment according to §35a (para. 1, sentence 11) Social Code Book V]
2023     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Olaparib (breast cancer, adjuvant) - Addendum to Commission A22-89]
2023     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Olopatadine/mometasone (allergic rhinitis) - Benefit assessment according to §35a Social Code Book V]
2023     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Clopidogrel, prasugrel, and ticagrelor for the prevention of atherothrombotic events in acute coronary syndrome]
2023     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Daridorexant (chronic insomnia) - Benefit assessment according to § 35a SGB V]
2023     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Tralokinumab (moderate-to-severe atopic dermatitis in adolescents) - Benefit assessment according to § 35a Social Code Book V]
2023     Scottish Health Technologies Group (SHTG) Orthotic bracing for the treatment of idiopathic scoliosis in children and young people (less than 18 years)
2023     Scottish Health Technologies Group (SHTG) Store-and-forward teledermatology for triage of primary care referrals
2023     Scottish Health Technologies Group (SHTG) Consideration of selective internal radiation therapies (SIRT) for treating primary hepatocellular carcinoma (liver cancer)
2023     Scottish Health Technologies Group (SHTG) An assessment of the Feeling Good app
2023     Scottish Health Technologies Group (SHTG) Placental growth factor (PlGF)-based testing to help diagnose suspected preterm pre-eclampsia
2023     Scottish Health Technologies Group (SHTG) Living donor transplantation
2023     Scottish Health Technologies Group (SHTG) Outpatient parenteral antimicrobial therapy (OPAT) cost calculator
2023     Scottish Health Technologies Group (SHTG) The cost-effectiveness of the Scottish Hip Fracture Audit
2023     Scottish Health Technologies Group (SHTG) The clinical effectiveness and cost effectiveness of a digital type 2 diabetes remission programme
2023     Scottish Health Technologies Group (SHTG) Outpatient biopsies (re-usable and disposable) equipment for suspicious laryngeal and pharyngeal lesions
2023     Scottish Health Technologies Group (SHTG) Community based respiratory care services for patients with chronic respiratory conditions
2023     Scottish Health Technologies Group (SHTG) Tumour profiling tests to guide chemotherapy decisions in early breast cancer
2023     Institut national d'excellence en sante et en services sociaux (INESSS) [Guides and standards: Syphilis - detection, diagnosis, optimal antibiotic use, and follow-up]
2023     Institut national d'excellence en sante et en services sociaux (INESSS) [Guides and standards: the management of myalgic encephalomyelitis / chronic fatigue syndrome]
2023     NIHR Public Health Research (PHR) programme Impact of a social prescribing intervention in North East England on adults with type 2 diabetes: the SPRING_NE multimethod study
2023     NIHR Public Health Research (PHR) programme A multicomponent psychosocial intervention to reduce substance use by adolescents involved in the criminal justice system: the RISKIT-CJS RCT
2023     NIHR Health Technology Assessment programme Total ankle replacement versus ankle arthrodesis for patients aged 50–85 years with end-stage ankle osteoarthritis: the TARVA RCT
2023     NIHR Health Technology Assessment programme Motivational support intervention to reduce smoking and increase physical activity in smokers not ready to quit: the TARS RCT
2023     Institut national d'excellence en sante et en services sociaux (INESSS) [Report: use of platelet-rich plasma for the treatment of knee osteoarthritis]
2023     Norwegian Institute of Public Health (NIPH) Treatments for relapsing and/or refractory multiple myeloma. A health technology assessment
2023     Belgian Health Care Knowledge Centre (KCE) Silicone adhesive multilayer foam dressings to prevent hospital-acquired pressure ulcers: a Belgian RCT-based economic evaluation
2023     Institut national d'excellence en sante et en services sociaux (INESSS) [Report: assessment of the relevance of tandem mass spectrometry-based newborn blood spot screening for very long-chain acyl-CoA dehydrogenase deficiency (VLCADD)]
2023     Institut national d'excellence en sante et en services sociaux (INESSS) [Report: assessment of the relevance of tandem mass spectrometry-based newborn blood spot screening for for long-chain acyl-CoA dehydrogenase deficiency (LCHADD) and mitochondrial trifunctional protein deficiency (TFPD)]
2023     Institut national d'excellence en sante et en services sociaux (INESSS) [Report: assessment of the relevance of tandem mass spectrometry-based newborn blood spot screening for glutaric acidemia type 1 (GA1)]
2023     The Federal Joint Committee (G-BA) Pharmaceutical Directive/Annex XII: Efgartigimod alfa (Myasthenia Gravis, AChR-antibody+)
2023     Institut national d'excellence en sante et en services sociaux (INESSS) [Guides and standards: update of the tool for choosing the dosage of monoclonal antibodies targeting PD 1 or PD-L1]
2023     Centre intégré universitaire de santé et de services sociaux de la Capitale-Nationale (CIUSSS) Assessment of hip protectors for users at risk of falls
2023     Scientific Advice Unit, avalia-t; The Galician Health Knowledge Agency (ACIS) [Early detection tools for emotional distress in adult people with cancer]
2023     Scientific Advice Unit, avalia-t; The Galician Health Knowledge Agency (ACIS) [Invasive monitoring of pulmonary artery pressure in patients with symptomatic heart failure]
2023     Scientific Advice Unit, avalia-t; The Galician Health Knowledge Agency (ACIS) [Efficacy and safety of Emotional Freedom Techniques for the treatment of anxiety, depression and post traumatic stress disorders]